Analysts See $-0.78 EPS for Audentes Therapeutics, Inc. (BOLD)

July 21, 2018 - By Richard Doty

Analysts expect Audentes Therapeutics, Inc. (NASDAQ:BOLD) to report $-0.78 EPS on August, 9.They anticipate $0.09 EPS change or 10.34 % from last quarter’s $-0.87 EPS. After having $-0.74 EPS previously, Audentes Therapeutics, Inc.’s analysts see 5.41 % EPS growth. The stock increased 1.92% or $0.78 during the last trading session, reaching $41.43. About 303,201 shares traded. Audentes Therapeutics, Inc. (NASDAQ:BOLD) has risen 142.34% since July 21, 2017 and is uptrending. It has outperformed by 129.77% the S&P500.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company has market cap of $1.52 billion. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It currently has negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.

More news for Audentes Therapeutics, Inc. (NASDAQ:BOLD) were recently published by: Benzinga.com, which released: “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” on June 26, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” and published on June 21, 2018 is yet another important article.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.